Showing 1 – 20 of 1778
Relevance | Newest | Oldest |
  • Stereotactic Radiotherapy Is Superior for Benign Brain Tumors

    Abstract Full Text
    JAMA. 2017; 318(8):690-690. doi: 10.1001/jama.2017.10995
  • JAMA June 20, 2017

    Figure 2: Kaplan-Meier Estimates of Overall Survival Among Patients Randomized to Bevacizumab or Cetuximab

    Tick marks on the curves denote the last known follow-up time for patients with no death date reported. The hazard ratio and P value are adjusted for prior adjuvant therapy, prior radiotherapy, protocol chemotherapy, and randomization before and after the amendment restricting eligibility to the KRAS wild-type tumor. Hazard ratio and P value for the RAS analysis are adjusted for prior adjuvant therapy, prior radiotherapy, protocol chemotherapy, and randomization before or after the amendment restricting eligibility to KRAS wild type tumor (KRAS is defined as exon 2 codons 12, 13; exon 4, codons 117, 146; exon 3 codons 59, 61 or NRAS: exon 2 codons 12, 13; exon 3 codons 59, 61; exon 4 codons 117, 146).
  • Determination

    Abstract Full Text
    JAMA. 2017; 317(19):1953-1954. doi: 10.1001/jama.2017.0629
  • Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years

    Abstract Full Text
    free access
    JAMA. 2017; 317(11):1126-1140. doi: 10.1001/jama.2017.1704

    This cohort study uses SEER registry data to compare adverse functional effects of managing localized prostate cancer with radical prostatectomy, external beam radiation, and active surveillance.

  • Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015

    Abstract Full Text
    free access is active quiz
    JAMA. 2017; 317(8):814-824. doi: 10.1001/jama.2017.0693

    This cohort study assesses the association between radiation and chemotherapy dose changes over time and risk of subsequent neoplasms among 5-year survivors of childhood cancer diagnosed between 1970 and 1990.

  • JAMA June 28, 2016

    Figure: Examples of Estimated Comparative Costs of High-Intensity Focused Ultrasound Partial Gland Ablation

    Costs modeled assuming 50% failure and progression and crossover to definitive therapy with intensity-modulated radiotherapy, through 5 years of follow-up. Costs for active surveillance and high-intensity focused ultrasound (HIFU) include preoperative multiparametric magnetic resonance imaging (mp-MRI) followed by annual mp-MRI and repeat biopsy as well as biannual prostate-specific antigen (PSA) testing and office visits. Biannual PSA testing and office visits are also modeled in surgery and radiotherapy costs.
  • Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2016; 315(17):1844-1853. doi: 10.1001/jama.2016.4324

    This randomized trial compares the effects of induction gemcitabine with vs without erlotinib in patients with locally advanced pancreatic cancer and, among those responsive to treatment, compares the effects of chemotherapy with vs without radiation.

  • Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer

    Abstract Full Text
    free access
    JAMA. 2015; 314(12):1291-1293. doi: 10.1001/jama.2015.8577

    This study uses long-term follow-up data from a randomized trial comparing radiation therapy with vs without androgen deprivation therapy for unfavorable-risk prostate cancer to compare survival and cause-specific mortality by severity of comorbidity.

  • JAMA September 22, 2015

    Figure: Overall Survival Stratified by Randomized Treatment Group

    The 15-year survival estimates for panel A were 27.58 (95% CI, 19.16-36.64) for radiation therapy (RT) alone vs 35.47 (95% CI, 26.20-44.84) for RT and androgen deprivation therapy (ADT); panel B, 30.52 (95% CI, 20.52-41.09) for RT alone vs 43.77 (95% CI, 32.41-54.56) for RT and ADT; panel C, 20.00 (95% CI, 7.28-37.20) for RT alone vs 8.33 (95% CI, 1.44-23.30) for RT and ADT. The 2-sided log-rank P value comparing survival in men across the 2 treatment groups was .22 for panel A, .04 for panel B, and .07 for panel C.aDescription of comorbidity based on the 4 grades (grade 0, none; grade 1, minimal; grade 2, moderate; and grade 3, severe) of the Adult Comorbidity Evaluation 27; the grade corresponds to the severity of the individual organ system decompensation and prognostic effect.
  • JAMA December 17, 2014

    Figure 1: Definition of Study Cohorts and Reasons for Exclusionsa

    aInitial inclusion criteria included that women be enrollees of commercial or Medicare Advantage plans, be at least 18 years old, have a diagnosis code for breast cancer, have been treated with lumpectomy, and have any code for radiation therapy appearing within 12 months of lumpectomy, and treated between 2008 and 2013. bExclusions applied sequentially. Patients could be excluded for more than 1 reason.
  • JAMA July 16, 2014

    Figure: New Practice-Changing Study Findings Presented at ASCO

    Overall survival of patients with low-grade glioma who received chemotherapy plus radiation therapy was 5.5 years longer than the overall survival of patients receiving radiation therapy alone.
  • Tadalafil for Prevention of Erectile Dysfunction After Radiotherapy for Prostate Cancer: The Radiation Therapy Oncology Group [0831] Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2014; 311(13):1300-1307. doi: 10.1001/jama.2014.2626

    In a randomized trial testing the efficacy of tadalafil with radiotherapy to treat prostate cancer, Pisansky and coauthors found that compared with placebo, 24 weeks of tadalafil daily did not result in in improved spontaneous, off-drug erectile function.

  • Glioblastoma and Other Malignant Gliomas: A Clinical Review

    Abstract Full Text
    is expired quiz
    JAMA. 2013; 310(17):1842-1850. doi: 10.1001/jama.2013.280319

    Omuro and DeAngelis review the clinical management of malignant gliomas, including genetic and environmental risk factors such as cell phones, diagnostic pitfalls, symptom management, specific antitumor therapy, and common complications.

  • Single- vs Multiple-Fraction Radiotherapy for Bone Metastases From Prostate Cancer

    Abstract Full Text
    free access
    JAMA. 2013; 310(14):1501-1502. doi: 10.1001/jama.2013.277081
  • Axillary Node Interventions in Breast Cancer: A Systematic Review

    Abstract Full Text
    is expired quiz
    JAMA. 2013; 310(13):1385-1394. doi: 10.1001/jama.2013.277804

    Rao and coauthors conducted a review of the literature to summarize evidence regarding the role of axillary interventions (surgical and nonsurgical) in breast cancer treatment and to review the association of these axillary interventions with recurrence of axillary node metastases, mortality, and morbidity outcomes in patients with breast cancer.

  • JAMA June 12, 2013

    Figure: Cumulative Prevalence of Chronic Health Conditions for Representative Groups of Organ-Specific Outcomes According to Age

    Curves reflect cumulative prevalences based on proportion of participants diagnosed with a condition before and after participation in the St Jude Lifetime Cohort Study (SJLIFE) and undergoing follow-up until October 31, 2012. aFor cardiomyopathy, at risk defined as radiation therapy to the heart or exposure to anthracycline or anthroquinone; for heart valve disorder, as radiation to the heart; for pituitary dysfunction, as radiation (≥18 Gy) to the hypothalamus-pituitary; for pulmonary dysfunction, as thoracotomy, radiation to the lungs, or exposure to bisulfan, carmustine/lomustine, or bleomycin; for hearing loss, as radiation (≥30 Gy) to the ear or exposure to cisplatin or carboplatin; for breast cancer, as female sex and radiation (≥20 Gy) to the breast. bAs part of the core assessment battery, all participants were evaluated for dyslipidemia and gonadal failure.
  • Prone vs Supine Positioning for Breast Cancer Radiotherapy

    Abstract Full Text
    free access
    JAMA. 2012; 308(9):861-863. doi: 10.1001/2012.jama.10759
  • Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin Lymphoma

    Abstract Full Text
    free access
    JAMA. 2012; 307(24):2609-2616. doi: 10.1001/jama.2012.5847
    In an unblinded study involving 88 children with Hodgkin lymphoma, Metzger et al compared the efficacy of 4 cycles of chemotherapy (VAMP) radiation with 2 cycles of VAMP. In an editorial, Whelan and Goldman discuss evolution of Hodgkin lymphoma treatment for children.
  • JAMA September 21, 2011

    Figure 2: Model-Predicted Probability of Functional Erections Suitable for Intercourse 2 Years After External Radiotherapy for Prostate Cancera

    Model-predicted probabilities based on pretreatment Expanded Prostate Cancer Index Composite sexual function score stratified by pretreatment prostate-specific antigen (PSA) level and planned use of neoadjuvant hormone therapy. Higher sexual function score denotes better sexual function. N=241 (39 [16%] with PSA level <4 ng/mL and 74 [31%] receiving neoadjuvant hormone therapy. aNote that curves for no use of neoadjuvant hormone therapy/PSA ≥4 ng/mL and use of neoadjuvant hormone therapy/PSA <4 ng/mL overlap.
  • Prediction of Erectile Function Following Treatment for Prostate Cancer

    Abstract Full Text
    free access has multimedia
    JAMA. 2011; 306(11):1205-1214. doi: 10.1001/jama.2011.1333